Khiron Life Sciences Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Khiron Life Sciences's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 17We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now
Jun 24We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate
May 03What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 06Revenue & Expenses Breakdown
How Khiron Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 16 | -31 | 22 | 2 |
30 Jun 22 | 16 | -30 | 23 | 2 |
31 Mar 22 | 15 | -33 | 25 | 1 |
31 Dec 21 | 13 | -33 | 26 | 1 |
30 Sep 21 | 12 | -16 | 26 | 1 |
30 Jun 21 | 10 | -19 | 27 | 1 |
31 Mar 21 | 9 | -20 | 27 | 1 |
31 Dec 20 | 8 | -24 | 29 | 2 |
30 Sep 20 | 8 | -30 | 32 | 2 |
30 Jun 20 | 9 | -34 | 36 | 3 |
31 Mar 20 | 9 | -38 | 37 | 4 |
31 Dec 19 | 10 | -36 | 35 | 4 |
30 Sep 19 | 8 | -35 | 31 | 3 |
30 Jun 19 | 5 | -29 | 25 | 3 |
31 Mar 19 | 3 | -26 | 23 | 1 |
31 Dec 18 | 1 | -20 | 19 | 0 |
30 Sep 18 | 0 | -16 | 15 | 0 |
30 Jun 18 | 0 | -12 | 11 | 0 |
31 Mar 18 | 0 | -6 | 6 | 0 |
Quality Earnings: Insufficient data to determine if KHRN.H has high quality earnings.
Growing Profit Margin: Insufficient data to determine if KHRN.H's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KHRN.H's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare KHRN.H's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if KHRN.H's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: KHRN.H has a negative Return on Equity (0%), as it is currently unprofitable.